Core Insights - The Sci-Tech Innovation Board (STAR Market) has officially launched, with a total market value exceeding 7 trillion yuan, showcasing the emergence of strong industrial clusters in various sectors [1] - Over six years, the STAR Market has fostered 589 "hard tech" listed companies, raising over 1.1 trillion yuan in direct financing, significantly reshaping the innovation ecosystem [1] - The board has successfully transformed over 120,000 invention patents into tangible benefits for society, enhancing public welfare [1] Industry Developments - In the integrated circuit sector, a complete industrial chain covering design, manufacturing, packaging, materials, and equipment has formed, with 120 listed companies leading the way [3] - Major players like SMIC and Huahong Semiconductor have achieved significant milestones, such as breaking international monopolies and reaching international quality standards [3] - The average R&D intensity of integrated circuit companies on the STAR Market is 22.5%, exceeding the industry average by 10 percentage points [3] Biopharmaceutical Sector - The STAR Market's fifth listing standard has opened crucial financing channels for unprofitable innovative drug companies, with 19 out of 20 companies under this standard successfully launching self-developed drugs [4] - Zai Lab, the first unprofitable drug company listed on the STAR Market, has achieved multiple innovative drug approvals, establishing itself as a benchmark for internationalization in drug innovation [4] High-end Equipment Manufacturing - The STAR Market has created a collaborative innovation matrix in high-end equipment manufacturing, with 127 companies covering critical industries such as high-speed rail and nuclear power [5] - China Railway Signal & Communication Corporation holds a 65% market share in high-speed rail signal control systems, ensuring the safety of the national high-speed rail network [5] Social Impact - The technological breakthroughs from the STAR Market have translated into real benefits for the public, significantly reducing drug prices and improving access to medical resources [6] - Innovative drugs have substantially lowered the economic burden on patients, with some treatments seeing price reductions of over 75% [6] - Domestic medical equipment has improved accessibility, with companies like United Imaging Healthcare breaking international monopolies and producing high-end medical devices [7] Financial Performance - Over 60% of STAR Market companies have introduced cash dividend plans, totaling 38.8 billion yuan, with over 290 companies distributing more than 30% of their profits [9] - The board has also seen significant share buyback and increase plans, with a total amount nearing 38 billion yuan [9] Institutional Innovations - The STAR Market has implemented continuous institutional innovations to address the financing challenges of "light asset, high R&D investment" companies, allowing for a higher refinancing ratio [10] - The establishment of the "Sci-Tech Growth Layer" provides a transitional platform for unprofitable tech companies, enhancing their growth prospects [10] Long-term Vision - The STAR Market has become a core nurturing ground for new productive forces, with 379 companies recognized as national "little giants" and 415 as manufacturing "champions" [12] - The board's R&D investment reached 168 billion yuan, more than three times its net profit, reflecting a strong commitment to innovation [12] - The ongoing reforms aim to further unleash the potential of the STAR Market, enhancing its role in both technological advancement and societal value [13]

证券代码：688521 证券简称：芯原股份 芯原微电子（上海）股份有限公司 二〇二五年七月 目 录 芯原微电子（上海）股份有限公司 2025 年第一次临时股东大会会议须知 ........ 2 芯原微电子（上海）股份有限公司 2025 年第一次临时股东大会会议议程 ........ 4 芯原微电子（上海）股份有限公司 2025 年第一次临时股东大会会议议案 ........ 7 芯原微电子（上海）股份有限公司 为了维护芯原微电子（上海）股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺利进行，根据 《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东会规则》以及《芯原微电子（上海） 股份有限公司章程》（以下简称"《公司章程》"）、《芯原微电子（上海）股份有 限公司股东大会议事规则》等相关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东或股东代理人 的合法权益，除出席会议的股东或股东代理人、公司董事、监事、高级管理人员、 见证律师及董事会邀请的人员外，公司有权 ...

证券代码：688521 证券简称：芯原股份 芯原微电子（上海）股份有限公司 2025 年第一次临时股东大会会议材料 二〇二五年七月 目 录 | 芯原微电子（上海）股份有限公司 | 年第一次临时股东大会会议须知 2025 | 2 | | --- | --- | --- | | 芯原微电子（上海）股份有限公司 | 2025 年第一次临时股东大会会议议程 | 4 | | 芯原微电子（上海）股份有限公司 | 年第一次临时股东大会会议议案 2025 | 7 | | 议案一 | 关于变更公司注册资本的议案 | 7 | | 议案二 | 关于取消监事会、修订公司章程并办理工商变更登记的议案 | 9 | | 议案三 | 关于修订《股东大会议事规则》的议案 | 10 | | 议案四 | 关于修订《董事会议事规则》的议案 | 11 | | 议案五 | 关于修订《对外投资管理制度》的议案 | 12 | | 议案六 | 关于修订《对外担保管理制度》的议案 | 13 | | 议案七 | 关于修订《关联交易管理制度》的议案 | 14 | | 议案八 | 关于修订《募集资金管理办法》的议案 | 15 | | 议案九 | 关于修订《累积投票制 ...

从中证科创创业半导体指数持仓样本的行业来看，集成电路设计占比57.35%、半导体设备占比 15.58%、集成电路制造占比15.37%、半导体材料占比7.43%、分立器件占比4.28%。 据了解，中证科创创业半导体指数从科创板和创业板中选取50只市值较大的半导体材料与设备、集成电 路、分立器件等半导体领域的上市公司证券作为指数样本，反映上述板块中半导体领域上市公司证券的 整体表现。该指数以2019年12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本数量比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数 样本定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进 行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理， 参照计算与维护细则处理。 金融界7月21日消息，上证指数高开高走，中证科创创业半导体指数 (科创创业半导体，932448)报 1711.78点。 从指数持仓来看，中证科创创业半导体指数十大权重分别为：中芯国 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688521 证券简称：芯原股份 公告编号：2025-037 芯原微电子（上海）股份有限公司 关于股份回购事项前十大股东 和前十大无限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 芯原微电子（上海）股份有限公司（以下简称"公司"）于2025年7月14日召开第二届董事会第二十三次 会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。公司全体董事出席会议，以 9票同意、0票反对、0票弃权的表决结果通过了该项议案。具体内容详见公司于2025年7月15日披露的 《关于以集中竞价交易方式回购股份的预案》（公告编号：2025-031）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司董事会披露回购股份决议前一个交易日（即2025年7月14日）登记在册的前十大股东和 前十大无限售条件股东的名称、持股数量及持股比例公告如下： 一、公司前十大股东持股情况 ■ 二、公司前十大无限售条 ...

证券代码：688521 证券简称：芯原股份 公告编号：2025-038 芯原微电子（上海）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为 股权激励股份 ；股票认购方式为 网下 ，上市股数为 本次股票上市流通总数为1,863,534股。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2020 年 7 月 21 日出具的《关于同意芯原微 电子（上海）股份有限公司首次公开发行股票注册的批复》（证监许可20201537 号），芯原微电子（上海）股份有限公司（以下简称"芯原股份"或"公司"）获 准首次向社会公开发行人民币普通股（A 股）股票 48,319,289 股。经上海证券交 易所同意，公司于 2020 年 8 月 18 日在上海证券交易所科创板挂牌上市。公司首 次公开发行完成后，总股本为 483,192,883 股，其中有限售条件流通股为 440,447,482 股，无限售条件流通股为 42,745,401 股。 本次上市流通的限售股为公司 2019 年股票期 ...

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

证券代码：688521 证券简称：芯原股份 公告编号：2025-038 芯原微电子（上海）股份有限公司 关于首次公开发行前股票期权行权限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 1,863,534股。 本次股票上市流通总数为1,863,534股。 本次股票上市流通日期为2025 年 7 月 28 日。 （一）限制性股票激励计划归属 由于公司实施《芯原微电子（上海）股份有限公司 2020 年限制性股票激励计 划》（以下简称"2020 年限制性股票激励计划"）及《芯原微电子（上海）股份有 限公司 2022 年限制性股票激励计划》（以下简称"2022 年限制性股票激励计划"）， 公司股本因 2020 年限制性股票激励计划及 2022 年限制性股票激励计划的归属登 记合计新增股份 3,102,150 股，具体情况如下： | 序号 | 股份变动时间 | | 股份变动事项 | 股份变动数量 | 公告索引 | | --- | --- ...

首次公开发行前股票期权行权限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 芯原微电子（上海）股份有限公司（以下简称"芯原股份"或"公司"）向特定 对象发行股票的持续督导机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等法律法规的相关规定，对芯原股份首次公开发行前股 票期权行权限售股上市流通的事项进行了核查，核查情况及核查意见如下： 国泰海通证券股份有限公司 关于芯原微电子（上海）股份有限公司 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2020 年 7 月 21 日出具的《关于同意芯原微 电子（上海）股份有限公司首次公开发行股票注册的批复》（证监许可[2020]1537 号），芯原微电子（上海）股份有限公司（以下简称"芯原股份"或"公司"）获准首 次向社会公开发行人民币普通股（A 股）股票 48,319,289 股。经上海证券交易所 同意，公司于 2020 年 8 月 18 日在上海证券交易所科创板挂牌上市。 本次上市流通的限售股为公司上市前制定的拟 ...

证券代码：688521 证券简称：芯原股份 公告编号：2025-037 | 序号 | 股东名称 | 持有数量（股） | 占公司总股本的比 例（%） | | --- | --- | --- | --- | | 1 | VeriSilicon Limited | 75,678,399 | 14.40 | | 2 | 富策控股有限公司 | 39,204,256 | 7.46 | | 3 | 国家集成电路产业投资基金股份 有限公司 | 34,724,272 | 6.61 | | 4 | 共青城时兴投资合伙企业（有限合 伙） | 24,523,402 | 4.66 | | 5 | 嘉兴海橙创业投资合伙企业（有限 | 20,573,708 | 3.91 | | | 合伙） | | | | --- | --- | --- | --- | | | 招商银行股份有限公司－华夏上 | | | | 6 | 证科创板 50 成份交易型开放式指 | 20,442,356 | 3.89 | | | 数证券投资基金 | | | | 7 | 上海浦东新兴产业投资有限公司 | 15,258,793 | 2.90 | | | 中国工商银行股份有 ...